Table 6.
Study | Imaging Modality Study Type |
Study Population | Optimization Criteria | % Patients Meeting the Optimization Criteria of the Total Image-Guided Patients | Followed Duration, mo | Key Endpoint (Optimal PCI vs Suboptimal PCI) |
---|---|---|---|---|---|---|
IVUS-XPL2 2015 | IVUS Random |
Long lesion (Stent ≥28 mm) | MSA ≥100% of the distal RLA | 54% (363/700 patients) | 12 | MACE(CD/TL-MI/ID-TLR): 1.5% vs 4.6% (HR: 0.31; 95% CI: 0.11-0.86) |
60 | MACE(CD/TL-MI/ID-TLR): 4.0% vs 7.4% (HR: 0.48; 95% CI: 0.28-0.83) | |||||
ULTIMATE8 2018 | IVUS Random |
All comers |
|
53% (384/724 patients) | 12 | TVF(CD/TV-MI/ID-TVR): 1.6% vs 4.4% (HR: 0.35; 95% CI: 0.14-0.90) |
36 | TVF(CD/TV-MI/ID-TVR): 4.2% vs 9.2% (HR: 0.44; 95% CI: 0.24-0.81) | |||||
Merged data of IVUS-XPL and ULTIMATE32 2022 | IVUS Pooled analysis |
Long lesion (Stent ≥28 mm) | Optimization criteria according to each trial’s definition | 52% (654/1,267 patients) | 36 | CD: 0.5% vs 1.5% (HR: 0.31; 95% CI: 0.08-1.15) MACE(CD/MI/ST): 0.5% vs 2.2% (HR: 0.22; 0.06-0.75) |
Merged data of 4 randomized trials61 2020 | IVUS Pooled analysis |
Long lesion (Stent ≥26 mm) or CTO | MSA ≥4.5 mm2 or MSA ≥80% of mead RLA | 41% (578/1,396) | 12 | MACE(CD/MI/ST/TVR): 1.9% vs 4.8% (HR: 0.34; 95% CI: 0.17-0.70) |
CLI-OPCI II56 2015 | OCT Registry |
All comers |
|
69% (679/984 lesions) | 10.4 | MACE(Death/MI/TLR): 7.1% vs 25.2% (HR: 0.23; 95% CI: 0.15-0.34) |
IVUS-ACS11 2024 | IVUS Random |
ACS |
|
79.9% (1,392/1,743 patients) | 12 | TVF(CD/TV-MI/ID-TVR): 3.2% vs 7.1% (P < 0.001) |